Valuation : SurModics

Market Cap 43Cr 37Cr 35Cr 32Cr 59Cr 4.04TCr 60Cr 411.18Cr 159.57Cr 2.06TCr 160.48Cr 156.97Cr 6.78TCr P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 42Cr 36Cr 34Cr 31Cr 58Cr 3.97TCr 59Cr 404.57Cr 157.01Cr 2.03TCr 157.9Cr 154.44Cr 6.67TCr EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
60.55
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 19/11/2025
Director of Finance/CFO 53 19/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 19/11/2025
Director/Board Member 53 19/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
19/11/25 Issuer sale

Executive/Senior Manager

1,71,148 1.1970%
19/11/25 Issuer sale

Director

35,847 0.2507%
19/11/25 Issuer sale

Controller/Auditor

24,311 0.1700%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+25.16%+18.73% 61Cr
+1.41%-3.18%-15.97%+7.41% 19TCr
+0.15%+0.17%-1.23%+12.24% 12TCr
+1.63%+2.61%+14.08%+92.25% 6.32TCr
-0.96%-1.14%+23.87%+47.11% 5.2TCr
+0.21%-1.41%-0.33%-32.66% 5.1TCr
-0.50%+0.82%+20.71%-11.98% 3.4TCr
+3.39%+4.97% - - 3.08TCr
+1.18%-2.08%+40.57%-15.96% 2.38TCr
+0.57%-3.01%-5.66%+14.32% 2.34TCr
Average +0.70%-0.44%+11.24%+14.61% 5.85TCr
Weighted average by Cap. +0.72%-1.72%+0.93%+16.25%

Financials

2023 2024
Net sales 13Cr 11Cr 11Cr 9.82Cr 18Cr 1.25TCr 18Cr 127.56Cr 50Cr 640.34Cr 50Cr 49Cr 2.1TCr 13Cr 11Cr 10Cr 9.34Cr 17Cr 1.19TCr 18Cr 121.3Cr 47Cr 608.92Cr 47Cr 46Cr 2TCr
Net income -15.36L -13.25L -12.48L -11.37L -21.26L -15Cr -21.42L -1.48Cr -57.35L -7.42Cr -57.68L -56.42L -24Cr -1.15Cr -99.57L -93.8L -85.46L -1.6Cr -109.03Cr -1.61Cr -11Cr -4.31Cr -56Cr -4.33Cr -4.24Cr -183.12Cr
Net Debt -1.21Cr -1.04Cr -98.34L -89.6L -1.67Cr -114.31Cr -1.69Cr -12Cr -4.52Cr -58Cr -4.54Cr -4.44Cr -191.99Cr -68.7L -59.27L -55.83L -50.87L -95.08L -65Cr -95.8L -6.61Cr -2.57Cr -33Cr -2.58Cr -2.52Cr -109Cr
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock